---
title: "Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291420150.md"
description: "A recent nonclinical study carried out at Stony Brook University contributes to the mounting evidence of effectiveness in various animal models of neuropathic pain. The study highlights the potential for treatment in this area, showcasing positive results in multiple animal models."
datetime: "2026-07-01T12:44:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291420150.md)
  - [en](https://longbridge.com/en/news/291420150.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291420150.md)
generator: "portal-rs"
---

# Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury

A recent nonclinical study carried out at Stony Brook University contributes to the mounting evidence of effectiveness in various animal models of neuropathic pain. The study highlights the potential for treatment in this area, showcasing positive results in multiple animal models.

### Related Stocks

- [ARTL.US](https://longbridge.com/en/quote/ARTL.US.md)

## Related News & Research

- [Artelo Biosciences reports positive preclinical data for ART27.13 in paclitaxel-induced peripheral neuropathy model](https://longbridge.com/en/news/292495956.md)
- [DWTX: Halneuron shows promise as a scalable, effective CINP therapy with strong Phase 2 results](https://longbridge.com/en/news/297686345.md)
- [06:00 ETNovaGo Therapeutics cierra una ronda de financiación para un estudio en lesiones agudas de la médula espinal](https://longbridge.com/en/news/297765618.md)
- [Novartis pauses autoimmune cell therapy studies after deaths, WSJ reports](https://longbridge.com/en/news/297596287.md)
- [Fate Therapeutics Expands Into Autoimmune Disease With New FT839 Trial](https://longbridge.com/en/news/297812155.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**